Taken together, our findings highlight a pro-tumoral function for the IL-25/ILC2 axis in NSCLC both in humans and in mice, suggesting that it may constitute a promising therapeutic target in NSCLC. This evidence concerns the gene IL25 and non-small cell lung carcinoma.